γδ T 细胞调节小细胞肺癌中的抗肿瘤免疫
γδ T cells modulate anti-tumor immunity in small cell lung cancer.
我们的发现表明,活化的γδ T细胞可能是SCLC治疗的有价值靶点。
英文原题:Bacterial outer-membrane vesicles promote Vγ9Vδ2 T cell oncolytic activity.
我们的发现首次表明,OMV刺激可促进Vγ9Vδ2 T细胞的扩增,这些细胞随后表现出抗肿瘤能力。我们提出,OMV介导的免疫激活利用了Vγ9Vδ2 T细胞的抗微生物/抗肿瘤能力,这一轴系可用于改进未来的治疗。
越来越多的证据表明,细菌外膜囊泡(OMVs)所引发的免疫激活能够启动强效的抗肿瘤免疫,促进对恶性细胞的识别和破坏。目前,这种反应背后的途径仍知之甚少,尽管已有研究提示γδ T细胞等固有样细胞可能参与其中。
来自健康供者的外周血单个核细胞(PBMCs)与大肠杆菌MG1655 Δ pal Δ lpxM OMVs共培养,并通过细胞标志物表达和细胞因子产生研究相应的免疫激活。OMV激活的γδ T细胞与癌细胞系共培养以测定细胞毒性。
这些囊泡诱导了广泛的炎症反应,其中γδ T细胞被观察到是在OMV刺激后增殖的主要细胞类型。值得注意的是,大多数γδ T细胞为Vγ9Vδ2型,已知该型细胞能对细菌代谢产物和肿瘤细胞上存在的应激标志物产生应答。我们观察到,在OMV介导的扩增后,Vγ9Vδ2 T细胞对乳腺癌和白血病细胞系(分别为SkBr3和Nalm6)均表现出强烈的细胞溶解活性。
BACKGROUND: Increasing evidence suggests the immune activation elicited by bacterial outer-membrane vesicles (OMVs) can initiate a potent anti-tumor immunity, facilitating the recognition and destruction of malignant cells. At present the pathways underlying this response remain poorly understood, though a role for innate-like cells such as γδ T cells has been suggested. METHODS: Peripheral blood mononuclear cells (PBMCs) from healthy donors were co-cultured with E. coli MG1655 Δ pal Δ lpxM OMVs and corresponding immune activation studied by cell marker expression and cytokine production. OMV-activated γδ T cells were co-cultured with cancer cell lines to determine cytotoxicity. RESULTS: The vesicles induced a broad inflammatory response with γδ T cells observed as the predominant cell type to proliferate post-OMV challenge. Notably, the majority of γδ T cells were of the Vγ9Vδ2 type, known to respond to both bacterial metabolites and stress markers present on tumor cells. We observed robust cytolytic activity of Vγ9Vδ2 T cells against both breast and leukaemia cell lines (SkBr3 and Nalm6 respectively) after OMV-mediated expansion. CONCLUSIONS: Our findings identify for the first time, that OMV-challenge stimulates the expansion of Vγ9Vδ2 T cells which subsequently present anti-tumor capabilities. We propose that OMV-mediated immune activation leverages the anti-microbial/anti-tumor capacity of Vγ9Vδ2 T cells, an axis amenable for improved future therapeutics.
MEMBER ACCOUNT
登录成功会直接打开下一页。